Literature DB >> 28799905

Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

James E Crowe1.   

Abstract

Antibodies are the principal immune effectors that mediate protection against reinfection following viral infection or vaccination. Robust techniques for human mAb isolation have been developed in the last decade. The study of human mAbs isolated from subjects with prior immunity has become a mainstay for rational structure-based, next-generation vaccine development. The plethora of detailed molecular and genetic studies coupling the structure of antigen-antibody complexes with their antiviral function has begun to reveal common principles of critical interactions on which we can build better vaccines and therapeutic antibodies. This review outlines the approaches to isolating and studying human antiviral mAbs and discusses the common principles underlying the basis for their activity. This review also examines progress toward the goal of achieving a comprehensive understanding of the chemical and physical basis for molecular recognition of viral surface proteins in order to build predictive molecular models that can be used for vaccine design.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Ebola virus; Marburg virus; antibodies; dengue virus; human; influenza virus; monoclonal antibodies; neutralization

Mesh:

Substances:

Year:  2017        PMID: 28799905      PMCID: PMC5700460          DOI: 10.1016/j.chom.2017.07.013

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  112 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.

Authors:  Bryan S Briney; Jordan R Willis; Mark D Hicar; James W Thomas; James E Crowe
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

4.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

5.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Authors:  C F Barbas; J E Crowe; D Cababa; T M Jones; S L Zebedee; B R Murphy; R M Chanock; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.

Authors:  Guntur Fibriansah; Kristie D Ibarra; Thiam-Seng Ng; Scott A Smith; Joanne L Tan; Xin-Ni Lim; Justin S G Ooi; Victor A Kostyuchenko; Jiaqi Wang; Aravinda M de Silva; Eva Harris; James E Crowe; Shee-Mei Lok
Journal:  Science       Date:  2015-07-03       Impact factor: 47.728

9.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Adamberage R de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Kristie D Ibarra; Jiaqi Wang; Eva Harris; Aravinda de Silva; James E Crowe; Shee-Mei Lok
Journal:  EMBO Mol Med       Date:  2014-01-13       Impact factor: 12.137

10.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  33 in total

1.  High frequency of shared clonotypes in human B cell receptor repertoires.

Authors:  Cinque Soto; Robin G Bombardi; Andre Branchizio; Nurgun Kose; Pranathi Matta; Alexander M Sevy; Robert S Sinkovits; Pavlo Gilchuk; Jessica A Finn; James E Crowe
Journal:  Nature       Date:  2019-02-13       Impact factor: 49.962

2.  Antibody Determinants of Influenza Immunity.

Authors:  James E Crowe
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 3.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

Review 4.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

5.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

6.  Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.

Authors:  Rui Kong; Hongying Duan; Zizhang Sheng; Kai Xu; Priyamvada Acharya; Xuejun Chen; Cheng Cheng; Adam S Dingens; Jason Gorman; Mallika Sastry; Chen-Hsiang Shen; Baoshan Zhang; Tongqing Zhou; Gwo-Yu Chuang; Cara W Chao; Ying Gu; Alexander J Jafari; Mark K Louder; Sijy O'Dell; Ariana P Rowshan; Elise G Viox; Yiran Wang; Chang W Choi; Martin M Corcoran; Angela R Corrigan; Venkata P Dandey; Edward T Eng; Hui Geng; Kathryn E Foulds; Yicheng Guo; Young D Kwon; Bob Lin; Kevin Liu; Rosemarie D Mason; Martha C Nason; Tiffany Y Ohr; Li Ou; Reda Rawi; Edward K Sarfo; Arne Schön; John P Todd; Shuishu Wang; Hui Wei; Winston Wu; James C Mullikin; Robert T Bailer; Nicole A Doria-Rose; Gunilla B Karlsson Hedestam; Diana G Scorpio; Julie Overbaugh; Jesse D Bloom; Bridget Carragher; Clinton S Potter; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Cell       Date:  2019-07-25       Impact factor: 41.582

7.  A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.

Authors:  Chunyan Wang; Rien van Haperen; Javier Gutiérrez-Álvarez; Wentao Li; Nisreen M A Okba; Irina Albulescu; Ivy Widjaja; Brenda van Dieren; Raul Fernandez-Delgado; Isabel Sola; Daniel L Hurdiss; Olalekan Daramola; Frank Grosveld; Frank J M van Kuppeveld; Bart L Haagmans; Luis Enjuanes; Dubravka Drabek; Berend-Jan Bosch
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

Review 8.  Influenza Virus-Specific Human Antibody Repertoire Studies.

Authors:  James E Crowe
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

Review 9.  Novel vaccines: Technology and development.

Authors:  Sarita U Patil; Wayne G Shreffler
Journal:  J Allergy Clin Immunol       Date:  2018-06-30       Impact factor: 10.793

10.  Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Hyon-Xhi Tan; Sheilajen Alcantara; Kathleen M Wragg; Matthew S Parsons; Amy W Chung; Jennifer A Juno; Stephen J Kent
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.